Novartis Ag

Hewlett Packard Enterprise Development LP

Akebia Therapeutics, Inc.

Flare Therapeutics Inc.

Xiaoyang Wang

Mark G Bock

John Richard Nelson

Min Wang

Fei Wang

Liladhar Murlidhar Waykole

Yubo Zhang

Michael Patrick Dillon

Piotr Henryk Karpinski

Dario Braga

Yves Auberson

Thomas Josef Troxler

Nikolaus Johannes Stiefl

Lv Liao

Thomas Ullrich

Stephanie Kay Dodd

Sven Weiler

Luca Arista

Stefano Luca Giaffreda

Rene Lattmann

Rita Ramos

Peggy Usselmann

Dimitrios Lizos

Tingying Zhu

Kai Cui

Xuechun Zhang

Yizong Zhou

Marco Curzi

Sreehari Babu

Jianwei Bian

Jialiang Li

Tie-Lin Wang

Haiyang Jiang

Valentina Molteni

David C Tully

Paul Vincent Rucker

Donatella Chianelli

Zhao Cao

Feifei Li

Jason Thomas Roland

Jonathan E Wilson

Jacob I Stuckey

Peter Wade

Shimin Chen

Runyan Li

Sudhir Ranjan

Hayang Jiang

Danmei Dai

Bo Zhou

Tielin Wang

Michael J Geier

James E Audia

Bo Zheng

Mark Gary Bock

Liqing Cong

Yaohui Huang

Mark E Scott

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

Provided herein are solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Vadadustat, Code: AKB-6548, Compound 1), compositions comprising such solid forms, and methods of making and using thereof. 

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Compositions and methods for modulating farnesoid X receptors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 

An event log system and method are disclosed. The system includes a plurality of worker nodes to receive and store event log records from a plurality of log sources, and a coordinator node to maintain information about mapping from the plurality of log sources to the plurality of worker nodes. Each worker node comprises an IngestKV module to temporarily store event log records from the log sources and a TimeRangeKV module to permanently store the event log records.

Event log system

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Carbamate/urea derivatives

Growing community of inventors

Shanghai, China

Xiaoyang Wang